Delaware jury rules in favour of Amgen in patent infringement case

Amgen today announced that a Delaware jury delivered a verdict in Amgen's favour in a trial on the validity of two Amgen patents that describe and claim monoclonal antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9).

Amgen brought the patent infringement action in the federal court of Delaware against Sanofi and Regeneron Pharmaceuticals, Inc.

Before trial, Sanofi and Regeneron had acknowledged infringement of seven patent claims in US Patent Numbers 8,829,165, and 8,859,741. The trial proceeded on the defendants' challenges to the validity of those seven claims. The jury found that the defendants had failed to prove the patents invalid for lack of written description and enablement. Prior to the case going to the jury, the court had dismissed the defendants' case on obviousness.

"We are thankful that the jury weighed the evidence carefully and recognised the validity of Amgen's patents on Repatha, our innovative biologic molecule that reduces LDL cholesterol," said Robert A Bradway, chairman and chief executive officer at Amgen.